ProPhase Labs, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $4.3M | $6.8M | $35.0M | $122.6M | $79.0M | $14.5M | $9.9M |
| Cost of Revenue | — | $3.0M | $6.9M | $19.4M | $52.0M | $37.1M | $9.9M | $7.3M |
| Gross Profit | — | $1.4M | $-150.0K | $15.6M | $70.7M | $42.0M | $4.6M | $2.6M |
| Gross Margin | — | 31.9% | -2.2% | 44.5% | 57.6% | 53.1% | 31.7% | 26.5% |
| Operating Expenses | ||||||||
| Research & Development | — | $107.0K | $594.0K | $1.4M | $652.0K | $520.0K | $633.0K | $332.0K |
| SG&A Expense | — | $19.3M | $37.9M | $33.4M | $34.4M | $22.5M | $7.5M | $4.5M |
| Operating Income | — | $-18.0M | $-38.6M | $-21.2M | $23.6M | $9.8M | $-2.1M | $-3.2M |
| Operating Margin | — | -415.4% | -570.6% | -60.7% | 19.2% | 12.4% | -14.3% | -32.8% |
| Interest Expense | — | — | — | $1.3M | $764.0K | $1.1M | $295.0K | — |
| Pretax Income | — | $-23.4M | $-42.3M | $-22.4M | $22.9M | $5.3M | $-2.3M | $-3.1M |
| Income Tax Expense | — | $0 | $7.2M | $-6.0M | $4.4M | $-968.0K | $12.0K | — |
| Net Income | — | $-14.7M | $-53.4M | $-16.8M | $18.5M | $6.3M | $-2.1M | $-3.1M |
| Net Margin | — | -339.3% | -788.2% | -48.0% | 15.1% | 7.9% | -14.6% | -31.9% |
| EPS (Basic) | — | $-1.74 | $-6.67 | $-0.25 | $0.29 | $0.10 | $-0.05 | $-0.07 |
| EPS (Diluted) | — | $-1.74 | $-6.67 | $-0.25 | $0.26 | $0.10 | $-0.05 | $-0.07 |
| Shares Outstanding (Basic) | 14.0M | 8.5M | 8.0M | 68.8M | 63.4M | 60.7M | 46.4M | 46.2M |
| Shares Outstanding (Diluted) | 14.0M | 8.5M | 8.0M | 68.8M | 74.6M | 73.6M | 46.4M | 46.2M |
| Dividends Per Share | — | — | — | — | — | $0.08 | — | — |